Polar Capital Holdings’s Vaxcyte PCVX Stock Holding History

Polar Capital Holdings’s Portfolio PCVX Stock Details PCVX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$82.9M	Sell	1,425,788 -246,995	-15%	-$13.4M	0.29%	72
2025 Q4	$77.2M	Buy	1,672,783 +1,257,253	+303%	+$56.2M	0.3%	78
2025 Q3	$15M	Sell	415,530 -410,265	-50%	-$13.6M	0.07%	174
2025 Q2	$26.8M	Sell	825,795 -256,678	-24%	-$8.41M	0.14%	123
2025 Q1	$40.9M	Buy	1,082,473 +108,828	+11%	+$8.7M	0.25%	109
2024 Q4	$79.7M	Sell	973,645 -22,134	-2%	-$2.2M	0.45%	60
2024 Q3	$114M	Buy	+995,779	New	+$89.7M	0.54%	44

Other funds holding PCVX

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Polar Capital Holdings's PCVX Position: Q1 2026 in Review

Polar Capital Holdings reduced its Vaxcyte (PCVX) stake by 15% in Q1 2026, selling an estimated $13.4M and leaving 1,425,788 shares worth $82.9M. The position accounts for 0.29% of the portfolio, ranked #72.

Polar Capital Holdings first reported a position in PCVX in Q3 2024 and has held it in 7 quarters since. The position peaked at $114M in Q3 2024. 336 funds tracked by Wall St. Rank hold PCVX as of Q1 2026.

Polar Capital Holdings held 1,425,788 shares of Vaxcyte worth $82.9M as of Q1 2026.
Polar Capital Holdings sold 246,995 Vaxcyte shares in Q1 2026, an estimated $13.4M.
Vaxcyte made up 0.29% of Polar Capital Holdings's portfolio in Q1 2026, its #72 holding.
Polar Capital Holdings first reported a position in Vaxcyte in Q3 2024 and has held it in 7 quarters since.
Polar Capital Holdings's Vaxcyte position peaked at $114M in Q3 2024.
336 funds tracked by Wall St. Rank held Vaxcyte as of Q1 2026.

Based on Polar Capital Holdings's 13F filing for Q1 2026, filed 15 May 2026.